Jupiter Asset Management Ltd. Increases Position in Guardant Health, Inc. $GH

Jupiter Asset Management Ltd. raised its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 102.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 421,328 shares of the company’s stock after purchasing an additional 213,512 shares during the period. Jupiter Asset Management Ltd. owned 0.33% of Guardant Health worth $43,034,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. V Square Quantitative Management LLC purchased a new stake in shares of Guardant Health in the 4th quarter worth approximately $27,000. Chesapeake Asset Management LLC bought a new stake in Guardant Health in the fourth quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Guardant Health in the fourth quarter worth $31,000. Elyxium Wealth LLC purchased a new stake in shares of Guardant Health in the fourth quarter worth $35,000. Finally, First Pacific Financial bought a new position in shares of Guardant Health during the fourth quarter valued at $43,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. BTIG Research set a $160.00 price target on Guardant Health and gave the stock a “buy” rating in a research report on Wednesday. Canaccord Genuity Group raised their price objective on shares of Guardant Health from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Friday, February 20th. Leerink Partners upped their target price on shares of Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a research note on Friday, February 20th. JPMorgan Chase & Co. increased their price target on shares of Guardant Health from $130.00 to $135.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Finally, Stifel Nicolaus boosted their price objective on shares of Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Nineteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Guardant Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $129.79.

Insider Activity at Guardant Health

In other news, Director Ian T. Clark sold 6,876 shares of the stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $106.90, for a total transaction of $735,044.40. Following the transaction, the director directly owned 2,975 shares of the company’s stock, valued at $318,027.50. This represents a 69.80% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Terilyn J. Monroe sold 3,832 shares of Guardant Health stock in a transaction on Monday, April 6th. The stock was sold at an average price of $92.68, for a total value of $355,149.76. Following the completion of the sale, the insider directly owned 20,990 shares of the company’s stock, valued at $1,945,353.20. The trade was a 15.44% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 331,244 shares of company stock valued at $36,025,966 over the last quarter. 5.60% of the stock is owned by company insiders.

Guardant Health Stock Performance

Shares of NASDAQ:GH opened at $133.22 on Friday. The firm has a market cap of $17.66 billion, a price-to-earnings ratio of -39.30 and a beta of 1.48. The business has a 50-day simple moving average of $94.23 and a two-hundred day simple moving average of $99.73. Guardant Health, Inc. has a fifty-two week low of $38.03 and a fifty-two week high of $133.71.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.